Sign in
CompletedPhase 2

Low-dose Atropine for the Prevention of Myopia Progression in Danish Children

Key facts

Who runs it
Line Kessel
Where
Denmark3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
97 people enrolled
Started
30 May 2019
Ended
23 Apr 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • 0.1% atropine and 0.01% atropine
  • 0.01% atropine
  • 0.9% Sodium-chloride
Record updated
29 June 2025

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Children aged ≥6-<9 years: myopia ≤-1 (spherical power) in at least one eye
  • Children aged ≥9-≤12 years: myopia ≤-2 (spherical power) in at least one eye
  • Cylinder less than 1.5 diopters

Who cannot take part

  • Previous eye surgery
  • Previous use of agents thought to affect myopia progression, e.g. atropine, pirenzepine or 7-methylxanthine (metabolite of caffeine and theobromine) and orthokeratology contact lenses
  • Collagen syndroms (Ehlers-Danlos syndrome, Marfan syndrome and Stickler syndrome)
  • Known allergy to atropine or any of the contents of the trial medication (active and in-active ingredients) used in the study
  • Serious systemic health troubles (e.g., cardiac or respiratory illness) and developmental disorders and delays
  • Myopia related to retinal dystrophies
  • Other ocular pathology (e.g., amblyopia, strabismus)
  • Non-compliance to eye examinations

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated with a risk of potentially blinding complications such as retinal detachment and myopic maculopathy. There is a direct association between the degree of myopia and the risk of complications. Myopia develops in childhood and during adolescence. To prevent higher degrees of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine eye drops have been shown to reduce myopia progression by 50% in Asian populations but its effect in non-Asian populations is unknown. The aim of this study is to investigate if low-dose atropine can reduce myopia progression in Danish children and teenagers. The study is an investigator initiated randomized clinical trial conducted as a collaboration between three Danish Eye Departments covering all of Denmark.

The 3 groups in the trial

  • Loading doseTreatment being tested

    In phase 1 (treatment phase), the participants (n=33) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime. In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.

    Treatment: 0.1% atropine and 0.01% atropine

  • Low doseTreatment being tested

    In phase 1 (treatment phase), the participants (n=32) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime. In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.

    Treatment: 0.01% atropine

  • PlaceboPlacebo, for comparison

    In phase 1 (treatment phase), the participants (n=32) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime. In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.

    Treatment: 0.9% Sodium-chloride

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Low-dose Atropine for the Prevention of Myopia Progression in Danish Children - a Randomized, Double-masked, Multicenter, 36-month Prospective 1:1:1 Study of Safety and Efficacy of 0.1% Atropine Loading Dose to Single 0.01% Atropine and Placebo
Publications
Record updated
29 June 2025